Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Gross Margin (2024 - 2025)

Celldex Therapeutics has reported Gross Margin over the past 6 years, most recently at 914.88% for Q4 2025.

  • Quarterly results put Gross Margin at 914.88% for Q4 2025, down 87751.0% from a year ago — trailing twelve months through Dec 2025 was 287.9% (down 30798.0% YoY), and the annual figure for FY2025 was 288.16%, down 30823.0%.
  • Gross Margin for Q4 2025 was 914.88% at Celldex Therapeutics, down from 111.51% in the prior quarter.
  • Over the last five years, Gross Margin for CLDX hit a ceiling of 66.34% in Q3 2024 and a floor of 914.88% in Q4 2025.